Login
Companies $CAPR
$8.20 -$0.10 (1.22%) After hours
CAPRICOR THERAPEUTICS, INC. logo

CAPRICOR THERAPEUTICS, INC.

capricor.com

What Do They Do?

Develops Deramiocel, a cell therapy for Duchenne muscular dystrophy, and exosome-based therapeutics and vaccines for rare diseases and other conditions.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −74% (Loss)
vs −$24.6M in Q3 FY2025
  • Aug 24, 2026 FDA extended the Deramiocel review deadline The agency classified an amendment with additional HOPE-3 data as major and set a new target action date.
  • May 7, 2026 Capricor sued its U.S. distribution partner The company seeks to end the distribution agreement and establish its right to distribute Deramiocel itself or through other distributors.

Deramiocel moves toward commercialization The older report described the DMD cell therapy in a clinical study; the latest report says its application is under FDA review and the company is preparing for possible commercialization.

Exosome vaccine enters human testing The older report described the engineered exosome vaccine as preclinical and said Capricor was seeking partners to move it into human testing; the latest report says a study run by the National Institutes of Health is underway.

Who Do They Compete With?

Competes with Sarepta Therapeutics and Nippon Shinyaku

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support